Coronary and uterine vascular responses to raloxifene in the sheep

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 3, 2000, Pages 521-528

  Zoma, Willie D ^b   Baker, R Scott ^b   Clark, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b NONE

Author keywords

Coronary blood flow; Estrogen; Ovine; Raloxifene; Uterine blood flow

Indexed keywords

ESTRADIOL; ESTROGEN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; RALOXIFENE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; FEMALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; SHEEP; UTERUS BLOOD FLOW; VASODILATATION;

EID: 0034030705     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.104205     Document Type: Article

References (25)

1. 1. Stampfer MJ, Colditz GA, Willet WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurse's health study. Obstet Gynecol 1998;72:23S-30S.
2. 2. Bush TL, Barrett-Conor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive estrogen use in women: results from the lipid research clinic's program follow-up study. Circulation 1987;75:1002-12.
3. 3. Weiner CP, Lizasoian I, Baylis SA, et al. Induction of calcium-dependent nitric oxide synthetase by sex hormones. Proc Natl Acad Sci U S A 1994;91:5212-6.
4. 4. Roselli M, Imthum B, Keller PJ, et al. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta estradiol and norethisterone acetate: A two year follow-up study. Hypertension 1995;25(Suppl):848-53.
5. 5. Darkow DJ, Lu L, White RE. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol 1997;272:H2765-73.
6. 6. Clark KE. Modulation of vascular responses by steroids. Curr Opin Endocrinol Diabetes 1997;4:392-400.
7. 7. Sack MN, Rader DJ, Cannon RO 3d. Oestrogen and oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-70.
8. 8. White MM, Zamudio S, Stevens T, et al. Estrogen, progesterone, and vascular Reactivity: Potential cellular mechanisms. Endocr Rev 1995;16:739-51.
9. 9. Brosnihan KB, Weddle D, Anthony MS, et al. Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. Hypertension 1997;15:715-26.
10. 10. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.
11. 11. Sato M, Bryant HU, Iversen P, et al. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J Pharmacol Exp Ther 1996;279:298-305.
12. 12. Sato M, Glasebrook AL, Bryant HU. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Metab 1995;12(Suppl 2):S9-S20.
13. 13. Brian WW, Lewis HK, Robert AW, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1.
14. 14. Van Buren AG, Yang D, Clark KE. Estrogen-induced uterine vasodilation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am J Obstet Gynecol 1992;167:828-33.
15. 15. Lang U, Baker RS, Clark KE. Estrogen-induced increases in coronary blood flow are antagonized by inhibitors of nitric oxide synthesis. Eur J Obstet Gynecol Reprod Biol 1997;74:229-35.
16. 16. Magness RR, Rosenfeld CR. Local and systemic estradiol-17 beta: effects on uterine and systemic vasodilation. Am J Physiol 1989;256:E536-42.
17. 17. Zeger SL, KY Liang. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
18. 18. Baker RS, Kopernik G, Lang U, et al. Local coronary infusion of estradiol-17β increases coronary blood flow [abstract]. J Soc Gynecol Investig 1997;4:178A.
19. 19. Bulletti C, de Ziegler D, Flamigni C, et al. Targeted drug delivery in gynecology: the first uterine pass effect. Hum Reprod 1997;12:1073-9.
20. 20. Hillard TC, Bourne TH, Whitehead MI, et al. Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. Fertil Steril 1992;58:959-63.
21. 21. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64.
22. 22. Hale O, Miles R, Howe S, et al. Raloxifene, a selective estrogen receptor modulator, inhibits estrogen stimulated proliferation of leiomyoma cells in culture [abstract]. J Soc Gynecol Investig 1996;3(Suppl 2):335A.
23. 23. Porter KB, Tsibris JCM, Porter SW, et al. Raloxifene causes rapid regression of abdominal wall leiomyomas in the estrogen-induced guinea pig model [abstract]. J Soc Gynecol Investig 1996;3(Suppl 2):147A.
24. 24. Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor-deficient mice. Nat Med 1997;3:545-8.
25. 25. Paech K, Webb P, Kuiper GGJM, et al. Differential ligand activation of estrogen receptors ER-α and ER-β at API Sites. Science 1997;277:1508-10.